TransMedics Group is reaffirmed as a strong buy due to its attractive valuation and significant growth prospects tied to expanding its multi-organ transplant platform. Key upcoming catalysts include clinical trials and European market expansion, which are crucial for meeting ambitious transplant volume goals by 2027. The company reported record Q3 2026 revenue of $203 million, a 41% increase year-over-year, prompting management to raise full-year 2026 revenue guidance to $764–$774 million with operating margins expected between 12.5% and 14%. Analysts project an annualized return of approximately 24% through 2030, supported by a resilient liver transplant business and potential upside from clinical and regulatory milestones.
TransMedics Group (TMDX) trades at USD 92.55 on Pluang as of Nov 11, 2026 22:01 WIB, which is closer to its 52-week low of USD 61.99 than its high of USD 150.42, showing a moderate recovery within its range. Despite a 1-day gain of 1.76%, all recent Pluang order activity is selling, indicating cautious investor sentiment. This contrasts with the company's optimistic outlook and raised revenue guidance for 2026.
